Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal A, C, W-135 and Y conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Meningococcal A, C, W-135 and Y conjugate vaccines are quadrivalent conjugate vaccines that prevent invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. They contain purified capsular polysaccharides from each serogroup covalently linked to a carrier protein (diphtheria toxoid, CRM197, or tetanus toxoid), converting the response to T cell–dependent immunity, which enhances immunogenicity and immune memory compared with plain polysaccharide vaccines. Three widely used formulations are MenACWY-D (Menactra; diphtheria toxoid conjugate), MenACWY-CRM (Menveo; CRM197 conjugate; supplied as one- or two-vial presentation), and MenACWY-TT (MenQuadfi; tetanus toxoid conjugate; ready-to-use solution). Indicated for active immunization across approved age ranges (from 2 months for Menveo; 2 years for MenQuadfi; 9 months historically for Menactra) to reduce the risk of meningococcal meningitis and septicemia. Administered intramuscularly with schedules and booster recommendations per age and risk; does not protect against serogroup B disease.
- Brand names
- MenactraMenveoMenQuadfi
- Other names
- MenACWY vaccinemeningococcal groups A, C, Y and W-135 conjugate vaccinequadrivalent meningococcal conjugate vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on meningococcal A, C, W-135 and Y conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal A, C, W-135 and Y conjugate vaccine.